Standard BioTools Inc. reports results for the quarter ended June 30 - Earnings Summary

Standard BioTools

05/08/2026 23:50

Standard BioTools Inc. LAB.OQ reported a quarterly adjusted loss of 3 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -9 cents.  The mean expectation of two analysts for the quarter was for a loss of one cent per share. Wall Street expected results to range from -3 cents tozero cents per share.
Revenue fell 52.1% to $20.10 million from a year ago; analysts expected $20.80 million. 
Standard BioTools Inc.'s reported EPS for the quarter was a loss of 7 cents​.
The company reported a quarterly loss of $26.76 million.
Standard BioTools Inc. shares had fallen by 0.3% this quarter and lost 35.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 40.9% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy" 
Wall Street's median 12-month price target for Standard BioTools Inc. is $1.55, about 47.1% above its last closing price of $0.82
This summary was machine generated from LSEG data August 5 at 10:50 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.01
-0.03
Missed
Mar. 31 2026 
-0.05
0.33
Beat
Dec. 31 2025 
-0.07
0.05
Beat
Sep. 30 2025 
-0.05
-0.09
Missed